MAPT and Alzheimer disease: Specifically, in Alzheimer’s disease (AD), the main cause of dementia worldwide, a reduction in amyloid β 42 (Aβ42) levels and an increase in phospho-tau in threonine 181 (p-tau) in CSF have been widely described and used in memory clinics to aid in the diagnosis of these patients [15,16,17].